Navigation Links
Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis

ion of aztreonam lysine for inhalation to our financial results could be adversely affected. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Annual Report on Form 10-K for the year ended December 31, 2006 and Quarterly Report on Form 10-Q for the first quarter of 2007, filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Contact

Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Nathan Kaiser, 650-522-1853 (Media)


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:3/27/2015)... CHINA AID, the ... Rehabilitation Medicine and Healthcare, second to none in ... held at Shanghai New International Expo Center on 22-24 ... Suggestions on Encouraging Private Capital to Participate in the ... issued by the Ministry of Civil Affairs of ...
(Date:3/27/2015)... March 27, 2015 According to ... (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, ... Indication (AF, VT, WPW) - Global Forecasts to 2019 ", ... to reach around ~$4.73 Billion by 2019 with a ... to 2019. Browse   90   ...
(Date:3/27/2015)... 2015   Hospira, Inc. (NYSE: ... the world,s leading provider of injectable drugs and ... evaluation of biosimilarity of its proposed biosimilar, Epoetin ... (FDA) conditionally approved name of RETACRIT™, compared to ... study data were presented at the National Kidney ...
Breaking Medicine Technology:CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... Amgen (NASDAQ: AMGN ) will present at the ... the Four Seasons Hotel, Boston, Mass., beginning at 8:35 a.m. ... Amgen, will present. Live audio of the presentation can be ... , under Investors. About Amgen ...
... to New England, many providers of durable medical equipment and ... responding to the havoc created by Hurricane Irene.  Of particular ... deadly for people who require a ventilator for ... and other lung diseases or chronic heart failure.   ...
Cached Medicine Technology:Hurricane Irene Spurs Emergency Home Medical Services for Patients 2Hurricane Irene Spurs Emergency Home Medical Services for Patients 3Hurricane Irene Spurs Emergency Home Medical Services for Patients 4
(Date:3/28/2015)... 28, 2015 India Network visitor ... made available to all visitors who purchase the plan ... members are encouraged to purchase the insurance program as ... of proper coverage for pre-existing medical conditions. Parents and ... two medical conditions with serious consequences to their health. ...
(Date:3/28/2015)... 28, 2015 Centurion Service Group will be ... Thursday, April 2 at their Las Vegas warehouse, located at ... The sale, which consists of equipment from hospitals and surgery ... 9 a.m. PDT. , Buyers will find items of ... “We are a one-stop-shop,” said Erik Tivin, CEO of Centurion. ...
(Date:3/28/2015)... 28, 2015 One in three young ... research presented today at the American Orthopaedic Society for ... examined the long term success of surgery for patients ... survey data from 242 patients who underwent ACL reconstruction ... Roe, MBBS, FRACS, from North Sydney Orthopaedic and Sports ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... stiffness may not be necessary, according to research presented ... ( AOSSM ) Specialty Day. , “Our study compared ... with 25 who underwent an additional glenohumeral joint capsule ... surgery,” commented George Murrell MD, PhD, lead author from ...
(Date:3/28/2015)... Genomic medicine experts have sequenced the genomes of ... time, key information for understanding and treating this intractable ... story on the Surviving Mesothelioma website. , ... British Columbia Cancer Agency, and PhenoPath lab in Seattle, ... and mutations that can lead to peritoneal mesothelioma ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... WASHINGTON, July 7 Cardinal Justin Rigali, Chairman of ... today to final guidelines for human embryonic stem cell ... (NIH). The text of his statement follows: , ... for destructive embryonic stem cell research, saying that under ...
... heart drugs get the wrong dose or end up on ... children, according to research led by the Johns Hopkins Children,s ... While the researchers found the highest number of ... children of all ages are vulnerable to such mistakes because ...
... -- Chemical dependency and recovery in patients and physicians ... editorials in the July 2009 issue of Mayo ... the immense challenges, including potential tragedies, of prescription chemical ... crucial overview, direction and optimism. Addiction to ...
... DVA ), a leading provider of kidney ... (CKD), today opened its 100th DaVita Academy - the ... new teammates (employees). On hand to participate and ... former United States Senator Paul Sarbanes and Congressman Elijah ...
... 7 DRINKiQ.com , Diageo,s cutting edge ... as the Most Outstanding Health and Wellness web site by ... was also named runner-up in the Education Category. Now ... excellence for communications professionals. The program is sanctioned by the ...
... Bonnie Yanelli ... ... a leading quality improvement and care management organization, named Bonnie Yanelli and Joseph Krolak as ... to increase KePRO,s market share and the company,s overall revenue. , , , , ...
Cached Medicine News:Health News:Cardinal Rigali Criticizes Final NIH Guidelines for Destructive Stem Cell Research 2Health News:Wrong dose of heart meds too frequent in children 2Health News:A comprehensive review of addiction to prescription painkillers among patients and physicians 2Health News:A comprehensive review of addiction to prescription painkillers among patients and physicians 3Health News:DaVita's Award-Winning Training Program for New Teammates Reaches Milestone With 100th DaVita Academy in Baltimore, Maryland 2Health News:Diageo's DRINKiQ.com Honored as Most Outstanding Health & Wellness Site by International Academy of the Visual Arts 2Health News:Diageo's DRINKiQ.com Honored as Most Outstanding Health & Wellness Site by International Academy of the Visual Arts 3Health News:KePRO Names Two New Business Development Directors 2
... expanded database containing over 330 species ... VITEK 2 Compact offers enhanced identification ... time (2 to 14 hours), it ... that contaminate production areas and final ...
... is a comprehensive hemodynamic monitoring and ... lab. Patient demographics, clinical hemodynamic ... procedural information all flow seamlessly into ... repetitive data entry. Both ...
... CritiSense first generation product is a ... via four physiological parameters, sensed at the ... state., CritiView illuminates tissue by low power ... emitted from the tissue. The light is ...
PowerMed is a billing software....
Medicine Products: